Genmab — August 2017
-
Forrygende nyhed.
-
Aktien skyder os pænt i vejret
-
The interim results of the ALCYONE study yet again illustrate the potential of daratumumab in multiple myeloma in combination with existing treatment regimens; this time with VMP in the front line setting. We are very pleased with the outcome of the pre-planned interim analysis in this study, which adds further to our hope that daratumumab could potentially become the critical driver redefining combination treatment in multiple myeloma," said Jan van de Winkel, Ph.D., Chief Executive Officer of
-
Kanon!!!
-
-
-
Os uden realtidskurser venter i spænding
-
@Tyndeejner pt 1387
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind